ASH
X
Nearly half of lymphoma patients alive after Gilead’s CAR-T therapy
https://pharmaphorum.com/news/nearly-half-of-lymphoma-patients-alive-after-gileads-car-t-therapy/
X
Medical meetings: Blockbuster or Netflix?
https://pharmaphorum.com/views-and-analysis/medical-meetings-blockbuster-or-netflix/
X
Celgene scores at ASH18 with double luspatercept data
https://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/
As rituximab biosimilars close in, Roche showcases Gazyva superiority
Andrew McConaghie
American Society of Haematology, ASH, biosimilars, Haematology
0 Comment
Roche faces competition against its blockbuster haematology drug
X
As rituximab biosimilars close in, Roche showcases Gazyva superiority
https://pharmaphorum.com/news/rituximab-biosimilars-close-roche-showcases-gazyva-superiority/
Spark reassures on safety of haemophilia gene therapy
Andrew McConaghie
ASH, cell and gene therapy, gene therapy, haemophilia, Hemophilia, Spark Therapeutics
0 Comment
Study of nine patients produce encouraging results
X
Spark reassures on safety of haemophilia gene therapy
https://pharmaphorum.com/news/spark-reassures-safety-haemophilia-gene-therapy/
CAR-Ts to take centre stage at ASH haematology congress
Andrew McConaghie
ASH, Haematology, haemophilia, hematology, Hemophilia, Sickle cell anaemia
0 Comment
X
CAR-Ts to take centre stage at ASH haematology congress
https://pharmaphorum.com/news/car-ts-take-centre-stage-haematology-congress/